• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.

作者信息

Sommers D K, Moncrieff J, Avenant J

机构信息

Department of Pharmacology, Pretoria, South Africa.

出版信息

Hum Toxicol. 1989 Sep;8(5):365-8. doi: 10.1177/096032718900800506.

DOI:10.1177/096032718900800506
PMID:2807305
Abstract
  1. The metabolic 4-hydroxylation of debrisoquine has been studied in a group of 98 black African villagers in Vendaland. 2. The metabolic alpha-hydroxylation of metoprolol has been studied in 94 of the same black African villagers. 3. A 4% prevalence of poor oxidative metabolism of debrisoquine and a 7.4% incidence of poor oxidation of metoprolol were found. The 4% result for debrisoquine differs considerably from the 19% found in San Bushmen, 30% in Hong Kong Chinese, 9% in Britains and 0% in Nigerians and Japanese, whilst the 7.4% result for metoprolol compares with 8.4% in Britains but differs from 0% in Nigerians and 4.1% in San Bushmen. 4. None of the poor oxidative metabolizers of debrisoquine were also poor oxidative metabolizers of metoprolol. This is contrary to results in British and Nigerian subjects where defective oxidation of metoprolol co-segrates with that of debrisoquine. 5. No similarities were found between the Venda metabolic ratio (MR) distributions and either extensive or poor MR distributions in Britains or Nigerians.
摘要

相似文献

1
Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
Hum Toxicol. 1989 Sep;8(5):365-8. doi: 10.1177/096032718900800506.
2
Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa.南非桑族布须曼人中的美托洛尔α-羟化多态性
Hum Toxicol. 1989 Jan;8(1):39-43. doi: 10.1177/096032718900800107.
3
Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.美托洛尔在白种人和尼日利亚人中的立体选择性代谢——与异喹胍氧化表型的关系。
Br J Clin Pharmacol. 1989 May;27(5):613-6. doi: 10.1111/j.1365-2125.1989.tb03424.x.
4
Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Hum Toxicol. 1988 May;7(3):273-6. doi: 10.1177/096032718800700308.
5
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中,美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
6
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.美托洛尔代谢与异喹胍氧化多态性——群体与家系研究
Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x.
7
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.尼日利亚人美托洛尔和异喹胍的代谢:缺乏多态性氧化的证据。
Clin Pharmacol Ther. 1986 Oct;40(4):387-94. doi: 10.1038/clpt.1986.195.
8
Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.尼日利亚人对司巴丁、异喹胍和美托洛尔代谢控制中解离现象的证据。
Pharmacogenetics. 1992 Apr;2(2):89-92. doi: 10.1097/00008571-199204000-00006.
9
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.日本人群中三种测试探针(美托洛尔、异喹胍和司巴丁)代谢率之间与遗传决定的氧化多态性的相关性。
Br J Clin Pharmacol. 1990 Jan;29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x.
10
Debrisoquine and metoprolol oxidation in Zambians: a population study.
Pharmacogenetics. 1993 Aug;3(4):205-8. doi: 10.1097/00008571-199308000-00005.

引用本文的文献

1
Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.了解影响伯氨喹安全性和疗效的人类遗传因素,以指导在南部非洲消除前环境中推出伯氨喹。
Malar J. 2018 Mar 20;17(1):120. doi: 10.1186/s12936-018-2271-z.
2
Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.南非队列中CYP2D6预测表型与实测表型的药物遗传学比较。
Pharmacogenomics J. 2016 Nov;16(6):566-572. doi: 10.1038/tpj.2015.76. Epub 2015 Oct 27.
3
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.
用于CYP2D6表型分析的探针药物和药代动力学指标评估。
Eur J Clin Pharmacol. 2007 Apr;63(4):321-33. doi: 10.1007/s00228-006-0250-8. Epub 2007 Feb 2.
4
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.多态性药物氧化的地理/种族差异。细胞色素P450(CYP)2D6和2C19的现有知识状况。
Clin Pharmacokinet. 1995 Sep;29(3):192-209. doi: 10.2165/00003088-199529030-00005.